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Nagasaki and Tokyo, JapanObjectives This study sought to determine whether systemic levels of pentraxin 3 (PTX3), a novel
inﬂammatory marker, are associated with thin-cap ﬁbroatheroma (TCFA).
Background Biomarkers predicting the presence of TCFA in vivo have not been established.
Methods We evaluated 75 patients (stable angina pectoris, n ¼ 47; acute coronary syndrome, n ¼ 28)
with de novo culprit lesions who were examined by optical coherence tomography and intravascular
ultrasound. We deﬁned TCFA as lipid-rich plaque with a ﬁbrous cap <65 mm thick. Systemic levels of
PTX3 were compared between patients with and without TCFA.
Results Thirty-eight and 37 patients with and without TCFA, respectively, were identiﬁed. Levels of
PTX3 were signiﬁcantly higher in patients with than in those without TCFA (p < 0.001) and correlated
inversely with ﬁbrous cap thickness (r ¼ 0.71, p ¼ 0.001) and positively with the remodeling index
(r ¼ 0.25, p ¼ 0.037). Multivariate logistic regression analysis showed that a higher PTX3 level was the
most powerful predictor of TCFA (odds ratio: 3.26, 95% conﬁdence interval: 1.75 to 6.05, p < 0.001).
Receiver-operating characteristic curve analysis showed that >3.24 ng/ml of PTX3 could predict TCFA
with 84% sensitivity and 86% speciﬁcity.
Conclusions Higher levels of systemic PTX3 are associated with TCFA. Systemic PTX3 levels comprise
a useful inﬂammatory marker that reﬂects coronary plaque vulnerability. (J Am Coll Cardiol Intv
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946Pathological studies of patients with sudden cardiac death
suggest that acute coronary syndromes (ACS) mostly arise as
a result of thrombotic coronary occlusion after rupture of
a thin-cap ﬁbroatheroma (TCFA), is also referred to as
vulnerable plaque (1). Vascular inﬂammation is considered
to play a key a role in plaque vulnerability (2).
Although acute-phase C-reactive protein (CRP) is widely
considered an indicator of systemic inﬂammation, the
response is not speciﬁc to vascular inﬂammation and is
triggered by many disorders that are unrelated to cardio-
vascular disease. Pentraxin 3 (PTX3) is a member of the
pentraxin superfamily that includes CRP and serum amyloid
P. High levels of PTX3 are locally expressed in vascular
endothelial, smooth muscle, and vascular inﬂammatory cellsAbbreviations
and Acronyms
ACS = acute coronary
syndromes
AMI = acute myocardial
infarction
CRP = C-reactive protein
CSA = cross-sectional area
EEM = external elastic
membrane
hs-CRP = high-sensitivity
C-reaction protein
IVUS = intravascular
ultrasound
OCT = optical coherence
tomography
PþM = plaque plus media
PTX3 = pentraxin 3
SAP = stable angina pectoris
TCFA = thin-cap
ﬁbroatheroma
UAP = unstable angina
pectorisin human atherosclerotic lesions
(3,4). Plasma PTX3 is also im-
plicated as an acute indicator and
a predictor of adverse clinical
outcomes of ACS (5,6). How-
ever, the association between
circulating PTX3 levels and
vulnerable plaque has not been
directly explored.
Optical coherence tomography
(OCT) is a new intravascular im-
aging modality that allows clear
visualization of the various features
of vulnerable plaques including
TCFA (7). When combined with
intravascular ultrasound (IVUS),
OCT is currently the optimal
approach to evaluating plaque
characteristics. Therefore, we
investigated whether systemic
PTX3 levels could reﬂect plaque
characteristics including TCFA in
coronary culprit lesions assessed by
OCT and IVUS.Methods
Study population. Between April 2009 and February 2012,
101 consecutive patients with coronary artery disease who
underwent both OCT and IVUS of de novo culprit lesions
in the native coronary artery at Nagasaki University Hospital
were considered for inclusion in this prospective study. The
exclusion criteria comprised left main lesions, ostial lesions,
chronic total occlusion or severely calciﬁed lesions, and
cardiogenic shock or renal insufﬁciency (baseline serum
creatinine >2.0 mg/dl without maintenance hemodialysis).
Patients with a history of treatment for or diagnosis of
carotid artery stenosis; thoracic/abdominal aortic aneurysm;
or peripheral artery, collagen, malignant, infectious, and
other systemic inﬂammatory diseases were also excludedbecause these conditions might affect PTX3 or CRP levels
(5,8). We excluded 22 patients according to these criteria
and 4 others with low-quality OCT or IVUS images. Thus,
data from 75 patients with ACS (n ¼ 28) and stable angina
pectoris (SAP) (n ¼ 47) were included in the ﬁnal analysis.
ACS included acute myocardial infarction (AMI) (n ¼ 17)
and unstable angina pectoris (UAP) (n ¼ 11). We deﬁned
AMI as chest pain that persisted for >30 min, arrival at
hospital within 12 h of the onset of chest pain, new ST-T
wave changes or a new left bundle branch block on a 12-lead
electrocardiogram and elevated cardiac markers (creatine
kinase-myocardial bound or troponin T) (9). We deﬁned
UAP as angina at rest, accelerated angina, or new-onset
angina without elevation of cardiac markers. We deﬁned
SAP as no change in the frequency, duration, or intensity of
angina symptoms within 6 weeks before admission. This
study complied with the Declaration of Helsinki with regard
to investigations in humans, and the Ethics Committee of
Nagasaki University Hospital approved the protocol. All
participants provided written, informed consent before
enrollment in the study.
Angiographic analysis. Patients were examined by quanti-
tative coronary angiography using a CASS II system (Pie
Medical Imaging, Maastricht, the Netherlands). The
minimum lumen diameter, reference vessel diameter, and
length of the culprit lesionweremeasured.Culprit lesionswere
identiﬁed from a combination of left ventricular wall motion
abnormalities, electrocardiographic ﬁndings, scintigraphic
defects, and angiographic lesion morphology.
OCT image acquisition and analysis. Patients with
a Thrombolysis In Myocardial Infarction ﬂow grade of 2 or
lower underwent aspiration thrombectomy using a Throm-
buster III aspiration catheter (Kaneka Medics, Tokyo, Japan)
before OCT imaging. We performed OCT using the balloon
occlusionmethod (10) and a0.016-inchguidewire-basedOCT
ImagingWire catheter (LightLab Imaging Inc., Westford,
Massachusetts) and a Helios occlusion balloon catheter
(Goodman Co. Ltd., Nagoya, Japan). An imaging run pro-
ceeded using automated pullback at 1.0 mm/s. Acquired OCT
images were analyzed using proprietary ofﬂine software from
LightLab Imaging.
Two independent experienced observers who were blin-
ded to the angiographic and clinical data analyzed the OCT
images using validated criteria for plaque characterization
(10). Discordance between observers was resolved by taking
a consensus reading. Signal-poor lesions with unclearly
delineated borders on OCT images indicated a lipid core
and signal-rich homogeneous lesions overlying a lipid core
indicated a ﬁbrous cap. The thinnest part of a ﬁbrous cap
was measured 3 times, and the average was deﬁned as
ﬁbrous cap thickness. The arc of a lipid core on cross-
sectional OCT images was measured and semiquantiﬁed
according to the number of involved quadrants. When
a lipid core comprised >2 quadrants, it was deemed to be
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 9 , 2 0 1 3 Koga et al.
S E P T E M B E R 2 0 1 3 : 9 4 5 – 5 4 Prediction of TCFA by PTX3
947lipid-rich plaque (Fig. 1A). We deﬁned TCFA as a lipid-
rich plaque with the thinnest part of the ﬁbrous cap
measuring <65 mm (Fig. 1B). Ruptured plaque was deﬁned
as ﬁbrous cap discontinuity and cavity formation in the
plaque (Fig. 1C). Intracoronary thrombus was identiﬁed as
a mass protruding into the vessel lumen from the surface of
the vessel wall (Fig. 1D). Intraobserver and interobserver
variability yielded acceptable concordance for the presence
of TCFA (k ¼ 0.81 and 0.84, respectively). The mean
interobserver and intraobserver differences in the ﬁbrous-cap
thickness were 5.9  6.6 and 5.2  5.7 mm, respectively.
Intraobserver and interobserver correlation coefﬁcients for
measurements of the ﬁbrous cap thickness were 0.85 and
0.82, respectively.
IVUS image acquisition and analysis. After OCT analysis,
IVUS images were obtained using the iLab system (Boston
Scientiﬁc, Natick, Massachusetts) and an Atlantis Pro
Imaging catheter (40 MHz, Boston Scientiﬁc) during
automated motorized pullback at 0.5 mm/s. Images were
digitally stored for subsequent off-line analysis.
The IVUS analysis proceeded using validated software
(echoPlaque 3.0, INDEC Medical Systems, Santa Clara,
California) according to the American College of CardiologyFigure 1. Representative Optical Coherence Tomography Images
(A) Lipid-rich plaque. (B) Thin-cap ﬁbroatheroma. Fibrous cap (arrows) is 60 mm thiClinical Expert Consensus Document (11). Cross-sectional
images were quantiﬁed for the lumen cross-sectional area
(CSA), external elastic membrane (EEM) CSA, and plaque
plus media (PþM) CSA calculated as EEM minus the
lumen CSA. Plaque burden was calculated as PþM divided
by the EEM CSA. The IVUS parameters were measured at
the minimum lumen CSA sites and a reference site. The
remodeling index was deﬁned as EEM CSA at the target
lesion divided by the EEMCSA at the average reference (12).
Blood samples. Venous blood samples were withdrawn
before coronary angiography from the forearms of patients
with ACS and SAP who had fasted overnight. The mean
interval from symptom onset to blood sampling from
patients with AMI was 6.4 h. Venous blood samples were
collected in ethylenediamine tetraacetic acid vacuum
containers for PTX3 and centrifuged for 10 min, and the
plasma was stored at 80C until assay. Levels of PTX3
were measured using a high-sensitivity enzyme-linked
immunosorbent assay system for human plasma (Perseus
Proteomics, Tokyo, Japan). The normal physiological
concentration of plasma PTX3 is w2 ng/ml (13). High-
sensitivity CRP (hsCRP) was measured at SRL Co. Ltd.
(Tokyo, Japan). The estimated glomerular ﬁltration rate wasck. (C) Ruptured plaque (arrow). (D) Intracoronary thrombus (arrowheads).
Table 2. Lesion Characteristics Determined by Angiography,
IVUS, and OCT
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948calculated as: 194  age0.287  serum creatinine1.094 (if
female,  0.739) (14).
Statistical analysis. Continuous values are expressed as mean
 SD for normally distributed variables or median (inter-
quartile range) for skewed variable, and analyzed by the
paired Student t, Mann-Whitney U, or Kruskal-Wallis test.
Categorical data are presented as numbers (%) and analyzed
using the chi-square or Fisher exact test. Relationships
between biomarkers and plaque characteristics were evalu-
ated using Spearman’s rank correlation coefﬁcient. Signi-
ﬁcant factors indicating the presence of TCFA were
determined using multivariate logistic regression analysis.
Factors with p < 0.05 in the univariate analysis were entered
into multivariable models. Receiver-operating characteristic
curves were constructed to identify optimal biomarker cutoff
points, deﬁned as the point closest to 100 in the top left
corner. Interobserver and intraobserver agreement for
TCFA identiﬁcation was evaluated by the Cohen k test of
concordance. Intraobserver and interobserver variability in
measuring ﬁbrous cap thickness values was evaluated by
linear regression. A value of p < 0.05 was considered
statistically signiﬁcant. All other data were statistically
analyzed using IBM SPSS version 20 (IBM Corp., Somers,
New York).Table 1. Patient Characteristics
Patients
Without TCFA
(n ¼ 37)
Patients
With TCFA
(n ¼ 38) p Value
Age, yrs 69  10 66  12 0.31
Male 30 (81) 30 (79) 0.82
ACS 5 (14) 23 (61) <0.001
AMI 0 17 (45)
UAP 5 (14) 6 (16)
Body mass index, kg/m2 23.8  3.4 23.5  3.6 0.66
Coronary risk factors
Hypertension 25 (68) 26 (68) 0.94
Hypercholesterolemia 18 (49) 16 (42) 0.57
Diabetes mellitus 16 (43) 8 (21) 0.050
Current smoker 7 (19) 15 (40) 0.075
Statin use 22 (60) 11 (29) 0.008
Lipid proﬁles, mg/dl
Total cholesterol 168  28 177  33 0.19
LDL cholesterol 98  24 110  34 0.10
HDL cholesterol 43  12 47  15 0.32
Triglyceride 110 (83–154) 92 (70–122) 0.058
Blood glucose proﬁles
Fasting blood glucose, mg/dl 95 (90–128) 100 (87–116) 0.92
HbA1c, % 5.5 (5.3–6.7) 5.3 (5.1–5.9) 0.021
eGFR, ml/min/1.73 m2 61.5  20.8 65.9  23.5 0.39
Values are mean  SD, n (%), or median (interquartile range).
ACS ¼ acute coronary syndrome; AMI ¼ acute myocardial infarction; HbA1c ¼ glycosylated
hemoglobin; eGFR ¼ estimated glomerular ﬁltration rate; HDL ¼ high-density lipoprotein;
LDL ¼ low-density lipoprotein; TCFA ¼ thin-cap ﬁbroatheroma; UAP ¼ unstable angina
pectoris.Results
Characteristics of patients. Among 75 culprit plaques in 75
patients, 38 (51%) of them were diagnosed as TCFA based
on OCT ﬁndings. Table 1 summarizes the baseline clinical
characteristics. The prevalence of ACS was higher, whereas
both the frequency of statin use and glycosylated hemo-
globin levels were lower in patients with than in those
without TCFA. No other characteristics signiﬁcantly
differed between patients with and without TCFA.
Angiographic, OCT, and IVUS ﬁndings. Table 2 shows the
angiographic, OCT, and IVUS ﬁndings in patients with and
without TCFA. Reference vessel diameter, EEM CSA,
PþM CSA, plaque burden, and remodeling index were
signiﬁcantly greater in patients with than in those without
TCFA. As expected from the deﬁnition of TCFA, the arc of
the lipid core was greater and the ﬁbrous cap was thinner in
patients with TCFA.
Relationships between PTX3, hsCRP, and lesion character-
istics. Table 3 compares PTX3 or hsCRP levels among the
lesion characteristics determined by OCT. Levels of PTX3Patients
Without TCFA
(n ¼ 37)
Patients
With TCFA
(n ¼ 38) p Value
Angiographic analysis
Multivessel disease 12 (32) 11 (29) 0.74
Culprit vessel 0.33
LAD 19 (54) 17 (45)
LCX 7 (19) 4 (11)
RCA 11 (30) 17 (45)
Lesion location 0.33
Proximal 12 (32) 17 (45)
Mid 13 (35) 14 (37)
Distal 12 (32) 7 (18)
QCA data
Reference vessel diameter, mm 2.66  0.46 3.03  0.55 0.003
Minimum lumen diameter, mm 0.84  0.33 0.88  0.42 0.70
Diameter stenosis, % 68  13 71  12 0.26
Lesion length, mm 13.9  7.2 16.7  8.7 0.14
OCT analysis
Fibrous cap thickness, mm 167 (100–296) 57 (50–59) <0.001
Arc of lipid core 134  47 198  58 <0.001
IVUS analysis
EEM CSA, mm2 11.3  4.8 16.8  5.7 <0.001
Lumen CSA, mm2 2.4  0.7 2.7  0.9 0.072
PþM CSA, mm2 8.9  4.5 14.1  5.4 <0.001
Plaque burden, % 77  8 83  6 0.01
Remodeling index 1.04  0.22 1.15  0.14 0.018
Values are n (%), mean  SD, or median (interquartile range).
CSA ¼ cross-sectional area; EEM ¼ external elastic membrane; IVUS ¼ intravascular ultra-
sound; LAD ¼ left anterior descending coronary artery; LCX ¼ left circumﬂex coronary artery;
OCT ¼ optical coherence tomography; PþM ¼ plaque plus media; QCA ¼ quantitative coro-
nary angiography; RCA ¼ right coronary artery; TCFA ¼ thin-cap ﬁbroatheroma.
Table 3. PTX3 and hsCRP Levels According to Lesion Characteristics Assessed by OCT
PTX3, ng/ml p Value hsCRP, mg/l p Value
Fibrous cap thickness, mm r ¼ 0.71 <0.001 r ¼ 0.24 0.050
Lipid core quadrants 0.002 0.21
1 (n ¼ 7) 1.87 (1.65–2.16) 0.62 (0.32–0.96)
2 (n ¼ 39) 3.19 (1.68–4.00) 1.12 (0.45–5.26)
3 (n ¼ 25) 4.07 (2.53–5.70) 1.45 (1.08–6.67)
4 (n ¼ 4) 8.18 (3.60–22.50) 1.29 (0.78–15.38)
TCFA <0.001 0.058
Yes (n ¼ 38) 4.54 (3.38–6.99) 1.49 (0.79–8.48)
No (n ¼ 37) 2.13 (1.55–2.64) 0.96 (0.47–3.93)
Ruptured plaque <0.001 0.002
Yes (n ¼ 20) 6.15 (3.82–13.53) 5.30 (1.17–18.70)
No (n ¼ 55) 2.51 (1.75–3.60) 0.96 (0.45–3.29)
Thrombus <0.001 0.031
Yes (n ¼ 27) 5.15 (3.19–10.27) 1.63 (0.94–14.80)
No (n ¼ 48) 2.34 (1.70–3.83) 1.03 (0.46–4.25)
Values are median (interquartile range).
hsCRP ¼ high-sensitivity C-reactive protein; PTX3 ¼ pentraxin 3; r ¼ Spearman’s rank correlation coefﬁcient; other abbreviations as in Table 2.
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949were signiﬁcantly higher in patients with than in those with-
out TCFA, but differences in hsCRP levels between patients
with and without TCFA did not reach signiﬁcance. Levels of
PTX3 signiﬁcantly and inversely correlated with ﬁbrous cap
thickness and tended to increase with increasing lipid quad-
rants. Levels of both PTX3 and hsCRP were signiﬁcantly
elevated in patients with ruptured plaque or thrombus.
Table 4 shows correlations between PTX3 or hsCRP
levels and QCA and IVUS data. Levels of PTX3 correlated
signiﬁcantly and positively with reference vessel diameter
and levels of both hsCRP and PTX3 correlated signiﬁcantly
and positively with EEM CSA, lumen CSA, PþM CSA
and the remodeling index.
On the other hand, PTX3 levels signiﬁcantly differed
between patients with ACS and those with SAP (4.90 ng/ml
[interquartile range (IQR): 3.31 to 9.53 ng/ml] vs. 2.33 ng/ml
[IQR: 1.68 to 3.58 ng/ml], respectively; p< 0.001). Similarly,Table 4. Levels of PTX3 and hsCRP According to QCA and IVUS Data
PTX3,
ng/ml p Value
hsCRP,
mg/l p Value
QCA analysis
Reference vessel diameter r ¼ 0.27 0.021 r ¼ 0.15 0.20
Minimum lumen diameter r ¼ 0.02 0.88 r ¼ 0.08 0.51
Lesion length r ¼ 0.05 0.67 r ¼ 0.03 0.79
IVUS analysis
EEM CSA r ¼ 0.43 <0.001 r ¼ 0.27 0.018
Lumen CSA r ¼ 0.25 0.033 r ¼ 0.23 0.048
PþM CSA r ¼ 0.40 <0.001 r ¼ 0.26 0.027
Plaque burden r ¼ 0.22 0.057 r ¼ 0.11 0.35
Remodeling index r ¼ 0.25 0.037 r ¼ 0.28 0.017
Abbreviations as in Tables 2 and 3.hsCRP levels also differed between ACS and SAP (5.30 mg/l
[IQR: 1.16 to 14.15 mg/l] vs. 0.89 mg/l [IQR: 0.40 to 3.04
mg/l], respectively; p< 0.001). Thus, we evaluated PTX3 and
hsCRP levels separately in patients with ACS and in those
with SAP because these values might be inﬂuenced by the
presence of ACS (Fig. 2). Among patients with ACS, PTX3
levels were signiﬁcantly higher in those with than in those
without TCFA (6.22 ng/ml [IQR: 3.80 to 14.52 ng/ml] vs.
2.50 ng/ml [IQR: 2.00 to 3.31 ng/ml]; p¼ 0.003) (Fig. 2A).
Among patients with SAP, PTX3 levels were higher in
patients with than without TCFA (3.58 ng/ml [IQR:
3.03 to 5.15 ng/ml] vs. 1.94 ng/ml [IQR: 1.44 to 2.68 ng/ml];
p < 0.001) (Fig. 2B). However, both patients with and
without TCFA had similar hsCRP levels in ACS (5.33 mg/l
[IQR: 1.12 to 20.00 mg/l] vs. 1.31 mg/l [IQR: 0.89 to
9.81 mg/l]; p¼ 0.41) (Fig. 2C) and in SAP (0.89 mg/l [IQR:
0.39 to 2.13 mg/l] vs. 0.83 mg/l [IQR: 0.41 to 3.26 mg/l];
p ¼ 0.85) (Fig. 2D).
The patients with ACS and SAP were categorized based
on whether PTX3 or hsCRP levels were in the lowest,
middle, and highest tertiles, and the frequency of TCFA was
compared in each group (Fig. 3). The frequency of TCFA
increased signiﬁcantly from the lowest to the highest tertiles
of PTX3 levels both in patients with SAP and in those with
ACS (Figs. 3A and 3B), but this trend was not evident
among hsCRP tertiles (Figs. 3C and 3D).
Predictors of TCFA. We used both univariate and multivar-
iate logistic regression analysis to identify signiﬁcant factors
predicting the presence of TCFA. The univariate analysis
identiﬁed ACS, higher PTX3 levels and remodeling index,
larger reference vessel diameter, EEM CSA, PþM CSA,
and plaque burden were signiﬁcant predictors of TCFA, and
complication of diabetes mellitus and statin use had lower
Figure 2. Comparisons of PTX3 and hsCRP Levels Based on the Presence of TCFA in Patients With ACS and SAP
Box and whisker plots show distribution of PTX3 (A, B) and hsCRP levels (C, D). ACS ¼ acute coronary syndrome; hsCRP ¼ high-sensitivity C-reactive protein;
PTX3 ¼ pentraxin 3; SAP ¼ stable angina pectoris; TCFA ¼ thin-cap ﬁbroatheroma.
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950probability of its presence. Among these factors, higher
PTX3 levels and larger PþM CSA values signiﬁcantly
correlated with TCFA with the multivariate analysis
(Table 5). We analyzed only patients with SAP to predict
the presence of TCFA in patients in whom ACS has not yet
developed. We found that a higher PTX3 level and a greater
reference vessel diameter were signiﬁcant factors associated
with TCFA in SAP patients (Table 6). Figure 4 shows the
receiver-operating characteristic curves of PTX3 levels for
predicting TCFA in all patients and in those with SAP. The
area under the curve of PTX3 in all patients (Fig. 4A) was
0.89 (95% conﬁdence interval: 0.81 to 0.97; p < 0.001). A
PTX3 cutoff value of 3.24 ng/ml distinguished TCFA from
non-TCFA with 84% sensitivity and 86% speciﬁcity. In
contrast, the area under the curve of PTX3 was 0.84 (95%
conﬁdence interval: 0.71 to 0.98; p < 0.001) in patients withSAP (Fig. 4B). A PTX3 value of 2.88 ng/ml identiﬁed
TCFA with 80% sensitivity and 78% speciﬁcity in these
patients.
Discussion
The main ﬁndings of the present study are as follows:
systemic PTX3 levels were signiﬁcantly higher in patients
with than in those without TCFA, the frequency of TCFA
signiﬁcantly increased according to elevations in PTX3
levels, and higher levels of PTX3 were the most powerful
predictor of TCFA in patients with SAP and the entire
study population.
The liver produces the short pentraxin CRP in response to
interleukin-6. Elevated CRP values correlate with increased
risk of cardiovascular disease in both healthy and high-risk
Figure 3. Frequency of TCFA According to PTX3 and hsCRP Levels
Comparison of TCFA frequency among PTX3 tertiles (A, B) or hsCRP levels (C, D) in patients with ACS and SAP. p Values indicate trends across tertiles. Abbreviations
as in Figure 2.
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951individuals (15). However, the CRP response is not speciﬁc
to vascular inﬂammation, and it can be triggered by various
disorders that are unrelated to cardiovascular disease. On the
other hand, endothelial cells, monocytes/macrophages, and
neutrophils locally produce long PTX3 at sites of inﬂam-
mation, predominantly in response to proinﬂammatory
signals including tumor necrosis factor-a, interleukin-1b,
oxidized low-density lipoprotein, and lipopolysaccharide
(3,4,16). Blood levels of PTX3 can increase in response to
subtle inﬂammation caused by coronary plaque. Circulating
plasma PTX3 is a predictor of adverse cardiac events in
patients with ACS as well as in those with SAP (5,6,17).
Furthermore, plasma PTX3 is more closely associated with
the angiographic complexity and severity of coronary artery
disease than hsCRP (18). However, whether systemic PTX3
levels can reﬂect plaque characteristics remains unclear. The
present study therefore evaluated the relationship betweensystemic PTX3 levels and coronary plaque vulnerability
assessed by OCT and IVUS.
The typical morphology of TCFA is that of a large plaque
burden, a large necrotic core, a thin ﬁbrous cap with inﬁl-
trating macrophages, and positive remodeling (19). We
evaluated these features of TCFA using OCT and IVUS
and found that patients with TCFA had signiﬁcantly higher
levels of systemic PTX3. We also discovered that systemic
PTX3 levels correlated inversely with ﬁbrous cap thickness
and positively with EEM CSA, PþM CSA, and the
remodeling index. Furthermore, the multivariate analysis
found that higher PTX3 levels were the most powerful
predictor of TCFA. We separately evaluated PTX3 levels in
patients with ACS and in those with SAP to control for any
inﬂuence that the presence of ACS may have had on PTX3
levels. Importantly, PTX3 levels were a signiﬁcant predictor
of TCFA, even in patients with SAP. These ﬁndings
Table 5. Logistic Regression Analysis of TCFA in All Patients
Univariate Multivariate
OR (95% CI) p Value OR (95% CI) p Value
ACS, yes 9.81 (3.12–30.84) <0.001
Diabetes mellitus, yes 0.35 (0.13–0.97) 0.043
Statin use, yes 0.28 (0.11–0.73) 0.009
PTX3, per 1 ng/ml 3.00 (1.75–5.16) <0.001 3.26 (1.75–6.05) <0.001
Reference vessel
diameter, per 0.1 mm
1.16 (1.04–1.30) 0.006
EEM CSA, per 1 mm2 1.23 (1.10–1.37) <0.001
PþM CSA, per 1 mm2 1.25 (1.11–1.40) <0.001 1.25 (1.07–1.46) 0.006
Plaque burden, per 1% 3.22 (1.52–6.84) 0.002
Remodeling index, per 0.1 1.39 (1.04–1.84) 0.024
CI ¼ conﬁdence interval; OR ¼ odds ratio; other abbreviations as in Tables 1 and 2.
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952suggest that systemic PTX3 levels reﬂect the vulnerability of
coronary culprit plaque. In addition, systemic PTX3 levels
might predict TCFA in patients with SAP who have not yet
developed ACS. This superior predictive value of PTX3
might be associated with the higher speciﬁcity of PTX3 for
localized inﬂammation. Thus, routinely measuring systemic
PTX3 levels in patients with SAP in daily clinical practice
can help to identify those who are likely to be at higher risk
of ACS. Iwata et al. (20) recently reported that statin
therapy (atorvastatin 10 mg/day) for 6 to 8 months signiﬁ-
cantly decreases the plasma PTX3 levels in patients with
SAP. Further study is needed to determine whether
reducing PTX3 levels with statin therapy can lead to the
prevention of ACS.
Levels of systemic PTX3 were signiﬁcantly higher in our
ACS patients with than in those without TCFA. Systemic
levels of PTX3 in such patients should be carefully inter-
preted. First, the major sources of systemic PTX3 in these
patients might be heart tissues with severe ischemia or
infarction rather than coronary vulnerable plaques. Nebuloni
et al. (21) found that PTX3 is produced by macrophages,
endothelium, and, to a lesser extent, myocardiocytes and
that it localizes in the interstitium of heart tissues of patients
with AMI at autopsy. Second, systemic PTX3 levels are
inﬂuenced by time-dependent changes from the onset ofTable 6. Logistic Regression Analysis of TCFA in Patients With SAP
Univariate Multivariate
OR (95% CI) p Value OR (95% CI) p Value
PTX3, per 1 ng/ml 2.50 (1.37–4.54) 0.003 2.42 (1.30–4.50) 0.005
Reference vessel
diameter, per 0.1 mm
1.19 (1.03–1.37) 0.016 1.23 (1.03–1.48) 0.023
EEM CSA, per 1 mm2 1.18 (1.04–1.34) 0.01
PþM CSA, per 1 mm2 1.19 (1.04–1.37) 0.011
Plaque burden, per 1% 1.12 (1.01–1.25) 0.034
Abbreviations as in Tables 1 to 5.AMI. Peri et al. (6) showed that plasma PTX3 levels peak at
a median of 7.5 h after AMI and return to normal after 3 days.
Our results might be biased by variations in intervals between
symptom onset in patients with AMI and blood sampling.
The present study identiﬁed a signiﬁcant relationship
between hsCRP and ruptured plaque or thrombus. Our
ﬁndings are consistent with those of previous IVUS and
OCT studies (22). In contrast, we did not discover a
signiﬁcant association between hsCRP and the presence of
TCFA. Tanaka et al. (23) reported that hsCRP levels
inversely correlate with ﬁbrous cap thickness measured by
OCT in patients with ACS. Matsuo et al. (24) showed by
using OCT that hsCRP levels are signiﬁcantly higher in
patients with ACS with than in those without TCFA.
Sawada et al. (25) found similar hsCRP levels in patients
who had SAP regardless of the presence or absence of
TCFA. The most likely explanation for these inconsistencies
might be as follows. Because the inﬂammatory responses of
coronary plaque might be subtle, TCFA alone might not
inﬂuence systemic inﬂammatory markers such as hsCRP,
especially in patients with SAP. Plaque rupture leading to
ACS might induce higher levels of systemic inﬂammation
compared with unruptured plaque and then increase hsCRP
levels in the peripheral circulation. However, the early
detection of unruptured TCFA as opposed to ruptured
plaque is more important for the prediction and prevention
of ACS. From this viewpoint, systemic hsCRP might be less
useful than PTX3.
In the present study, diabetes mellitus had a lower
probability for predicting TCFA by only a univariate anal-
ysis. In contrast, a previous OCT study demonstrated that
plaques in patients with diabetes frequently had vulnerable
features including TCFA (26). This disagreement might be
caused by the ﬁnding that our patients with diabetes had
a signiﬁcantly higher proportion of statin use than those
without diabetes (63% vs. 35%, p ¼ 0.027).
We could not ascertain a causal relationship between
elevated PTX3 and coronary plaque characteristics. Sav-
chenko et al. (4) reported that PTX3 might play a causal role
in the progression of atherosclerotic lesions through soluble
pattern recognition in innate immunity. In contrast, PTX3 in
apolipoprotein E knockout mice was recently implicated in
an atheroprotective effect (27), and it has a cardioprotective
role in mouse models of AMI (28). Elevated PTX3 levels
might reﬂect a compensatory cardioprotective response to an
activated inﬂammatory response. However, the present study
found only that systemic PTX3 is a useful inﬂammatory
marker of TCFA. The pathogenic role of elevated PTX3 in
coronary plaque vulnerability requires further study.
Study limitations. First, the small patient cohort from a
single center imposed inherent limitations. In addition,
because we evaluated only limited patients who did not meet
many exclusion criteria and who underwent both OCT and
IVUS, our results could have been affected by selection bias
Figure 4. Receiver-Operating Curves of PTX3 Levels for Predicting TCFA
The AUC of PTX3 levels were obtained from all patients (A) and from patients with SAP (B). AUC ¼ area under the curve; other abbreviations as in Figure 2.
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953and cannot be generalized to all patients. Second, we
assessed only culprit plaque morphology in culprit vessels.
Assessment of multiple plaques by OCT in 3-vessel coro-
nary trees is ethically unacceptable, especially in patients
with ACS because repeated balloon occlusion is required
along with a larger volume of ﬂushing solution. Third,
although we did not enroll patients with carotid artery
stenosis, thoracic/abdominal aortic aneurysms, or peripheral
artery disease, we could not exclude the possibility that
vulnerable plaques in other vascular beds might affect PTX3
levels. To demonstrate local PTX3 production in the coro-
nary circulation, PTX3 levels should also be measured at the
coronary sinus or coronary artery. Fourth, several thrombi
might reduce the ability of OCT to assess the details of plaque
morphology, because thrombus might shadow or obscure
underlying structures. Finally, we did not assess whether
PTX3 levels can predict clinical outcomes and whether
TCFA would lead to ACS in the future. Future longitudinal
and prospective studies are needed to address these issues.Conclusions
Levels of systemic PTX3 are higher in patients with than in
those without TCFA assessed by OCT. Higher PTX3 levels
comprise a powerful indicator of TCFA, even in patients
with SAP. These ﬁndings suggest that systemic PTX3 can
serve as a biomarker that reﬂects plaque vulnerability.
Reprint requests and correspondence: Dr. Satoshi Ikeda,
Department of Cardiovascular Medicine, Nagasaki University
Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Naga-
saki 852-8501, Japan. E-mail: sikeda@nagasaki-u.ac.jp.REFERENCES
1. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons
from sudden coronary death: a comprehensive morphological classiﬁ-
cation scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol
2000;20:1262–75.
2. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell 2001;104:
503–16.
3. Rolph MS. Production of the long pentraxin PTX3 in advanced athero-
sclerotic plaques. Arterioscler Thromb Vasc Biol 2002;22. 10e–14.
4. Savchenko A, Imamura M, Ohashi R, et al. Expression of pen-
traxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 2008;
215:48–55.
5. Inoue K, Sugiyama A, Reid PC, et al. Establishment of a high sensi-
tivity plasma assay for human pentraxin3 as a marker for unstable angina
pectoris. Arterioscler Thromb Vasc Biol 2007;27:161–7.
6. Peri G, Introna M, Corradi D, et al. PTX3, a prototypical long pen-
traxin, is an early indicator of acute myocardial infarction in humans.
Circulation 2000;102:636–41.
7. Jang IK, Tearney GJ, MacNeill B, et al. In vivo characterization of
coronary atherosclerotic plaque by use of optical coherence tomography.
Circulation 2005;111:1551–5.
8. Inoue K, Kodama T, Daida H. Pentraxin 3: a novel biomarker for
inﬂammatory cardiovascular disease. Int J Vasc Med 2012;2012:657025.
9. Thygesen K, Alpert JS, White HD. Universal deﬁnition of myocardial
infarction. J Am Coll Cardiol 2007;50:2173–95.
10. Tearney GJ, Regar E, Akasaka T, et al. Consensus standards for
acquisition, measurement, and reporting of intravascular optical coher-
ence tomography studies: a report from the International Working
Group for Intravascular Optical Coherence Tomography Standardiza-
tion and Validation. J Am Coll Cardiol 2012;59:1058–72.
11. Mintz GS, Nissen SE, Anderson WD, et al. American College of
Cardiology Clinical Expert Consensus Document on Standards for
Acquisition, Measurement and Reporting of Intravascular Ultrasound
Studies (IVUS). A report of the American College of Cardiology Task
Force on Clinical Expert Consensus Documents. J Am Coll Cardiol
2001;37:1478–92.
12. Garcia-Garcia HM, Costa MA, Serruys PW. Imaging of coronary
atherosclerosis: intravascular ultrasound. Eur Heart J 2010;31:2456–69.
13. Yamasaki K, Kurimura M, Kasai T, Sagara M, Kodama T, Inoue K.
Determination of physiological plasma pentraxin 3 (PTX3) levels in
healthy populations. Clin Chem Lab Med 2009;47:471–7.
14. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated
GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:
982–92.
Koga et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 9 , 2 0 1 3
Prediction of TCFA by PTX3 S E P T E M B E R 2 0 1 3 : 9 4 5 – 5 4
95415. Albert MA, Ridker PM. The role of C-reactive protein in cardiovas-
cular disease risk. Curr Cardiol Rep 1999;1:99–104.
16. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the
crossroads between innate immunity, inﬂammation, matrix deposition,
and female fertility. Annu Rev Immunol 2005;23:337–66.
17. Dubin R, Li Y, Ix JH, Shlipak MG, Whooley M, Peralta CA. Asso-
ciations of pentraxin-3 with cardiovascular events, incident heart failure,
and mortality among persons with coronary heart disease: data from the
Heart and Soul Study. Am Heart J 2012;163:274–9.
18. Karakas MF, Buyukkaya E, Kurt M, et al. Serum pentraxin 3 levels
are associated with the complexity and severity of coronary artery
disease in patients with stable angina pectoris. J Investig Med 2013;
61:278–85.
19. Vancraeynest D, Pasquet A, Roelants V, Gerber BL, Vanoverschelde JL.
Imaging the vulnerable plaque. J Am Coll Cardiol 2011;57:1961–79.
20. Iwata A, Miura S, Tanaka T, et al. Plasma pentraxin-3 levels are
associated with coronary plaque vulnerability and are decreased by statin.
Coron Artery Dis 2012;23:315–21.
21. Nebuloni M, Pasqualini F, Zerbi P, et al. PTX3 expression in the heart
tissues of patients with myocardial infarction and infectious myocarditis.
Cardiovasc Pathol 2011;20:e27–35.
22. Tanaka A, Shimada K, Sano T, et al. Multiple plaque rupture and
C-reactive protein in acute myocardial infarction. J Am Coll Cardiol
2005;45:1594–9.23. Tanaka A, Imanishi T, Kitabata H, et al. Morphology of exertion-
triggered plaque rupture in patients with acute coronary syndrome:
an optical coherence tomography study. Circulation 2008;118:
2368–73.
24. Matsuo Y, Kubo T, Okumoto Y, et al. Circulating malondialdehyde-
modiﬁed low-density lipoprotein levels are associated with the presence of
thin-cap ﬁbroatheromas determined by optical coherence tomography in
coronary artery disease. Eur Heart J Cardiovasc Imaging 2013;14:43–50.
25. Sawada T, Shite J, Shinke T, et al. Low plasma adiponectin levels are
associated with presence of thin-cap ﬁbroatheroma in men with stable
coronary artery disease. Int J Cardiol 2010;142:250–6.
26. KatoK, YonetsuT, KimSJ, et al. Comparison of nonculprit coronary plaque
characteristics between patients with and without diabetes: a 3-vessel optical
coherence tomography study. J Am Coll Cardiol Intv 2012;5:1150–8.
27. Norata GD, Marchesi P, Pulakazhi Venu VK, et al. Deﬁciency of the
long pentraxin PTX3 promotes vascular inﬂammation and atheroscle-
rosis. Circulation 2009;120:699–708.
28. Salio M, Chimenti S, De Angelis N, et al. Cardioprotective function of
the long pentraxin PTX3 in acute myocardial infarction. Circulation
2008;117:1055–64.
Key Words: optical coherence tomography - pentraxin 3 -
thin-cap ﬁbroatheroma - vulnerable plaque.
